Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer

NCT06670300 is registered in ClinicalTrials.gov with YongZhang as lead sponsor.

NCT NCT06670300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06670300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Lead sponsor
YongZhang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

participants who had received second-line or higher advanced melanoma and advanced renal cancer